Neurotech International (CHIA:NTI) - Stock Price, News & Analysis

NTI Stock Overview

A clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. More details

NTI fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 44.67% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Does not have a meaningful market cap (A$63M)

Does not have meaningful revenue (A$3M)

Neurotech International Limited Competitors

CurveBeam AI

ASX:CVB

AU$41.4m

Micro-X

ASX:MX1

AU$39.0m

CardieX

ASX:CDX

AU$35.3m

SomnoMed

ASX:SOM

AU$60.5m

Price History & Performance

Summary of all time highs, changes and price drops for Neurotech International
Historical stock prices
Current Share Price	AU$0.061
52 Week High	AU$0.13
52 Week Low	AU$0.048
Beta	1.48
11 Month Change	12.96%
3 Month Change	-14.08%
1 Year Change	10.91%
33 Year Change	-7.58%
5 Year Change	238.89%
Change since IPO	-75.10%

Recent updates

Shareholder Returns

	NTI	AU Medical Equipment	AU Market
7D	8.9%	0.6%	1.4%
1Y	10.9%	15.3%	17.7%

Return vs Industry: NTI underperformed the Australian Medical Equipment industry which returned 12.8% over the past year.

Return vs Market: NTI underperformed the Australian Market which returned 16.9% over the past year.

Price Volatility

Is NTI's price volatile compared to industry and market?
NTI volatility
NTI Average Weekly Movement	7.6%
Medical Equipment Industry Average Movement	9.0%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

Stable Share Price: NTI has not had significant price volatility in the past 3 months compared to the Australian market.

Volatility Over Time: NTI's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2016	n/a	Peter James Griffiths	www.neurotechinternational.com

Neurotech International Limited, a clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is focused on development and commercialization of NTI164 for multiple paediatric neurological disorders; and Mente, a clinically proven home therapy aimed at enhancing engagement and relaxation in autistic children exhibiting elevated delta band brain activity. It also engages in executing medical research projects; and developing technological devices.

Neurotech International Limited Fundamentals Summary

How do Neurotech International's earnings and revenue compare to its market cap?
NTI fundamental statistics
Market cap	AU$63.11m
Earnings (TTM)	-AU$5.07m
Revenue (TTM)	AU$3.18m

19.9x

P/S Ratio

-12.4x

P/E Ratio

Is NTI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NTI income statement (TTM)
Revenue	AU$3.18m
Cost of Revenue	AU$7.83k
Gross Profit	AU$3.17m
Other Expenses	AU$8.24m
Earnings	-AU$5.07m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.0049
Gross Margin	99.75%
Net Profit Margin	-159.54%
Debt/Equity Ratio	0%

How did NTI perform over the long term?

See historical performance and comparison

NTI Stock Overview

Rewards

Risk Analysis

Neurotech International Limited Competitors

ASX:CVB

AU$41.4m

ASX:MX1

AU$39.0m

ASX:CDX

AU$35.3m

ASX:SOM

AU$60.5m

Price History & Performance

Recent News & Updates

Now 22% overvalued

Now 20% overvalued

Neurotech International Limited, Annual General Meeting, Nov 20, 2024

Full year 2024 earnings released: AU$0.006 loss per share (vs AU$0.01 loss in FY 2023)

Less than half of directors are independent

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Recent updates

Now 22% overvalued

Now 20% overvalued

Neurotech International Limited, Annual General Meeting, Nov 20, 2024

Full year 2024 earnings released: AU$0.006 loss per share (vs AU$0.01 loss in FY 2023)

Less than half of directors are independent

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Neurotech International Limited to Report Q1, 2024 Results on Oct 27, 2023

Neurotech International Limited, Annual General Meeting, Nov 15, 2023

Full year 2023 earnings released: AU$0.01 loss per share (vs AU$0.005 loss in FY 2022)

New minor risk - Financial data availability

Neurotech International Limited to Report Q4, 2023 Results on Jul 26, 2023

First half 2023 earnings released: AU$0.48 loss per share (vs AU$0.003 loss in 1H 2022)

Neurotech International Limited Announces First Patient Treated in Phase I/II PANDAS/PANS Trial

Neurotech International Limited Announces Approval for Additional Phase I/II ASD Trial Extension

Neurotech International Limited Receives HREC Approval for Phase I/II PANDAS/PANS Clinical Trial

Neurotech International Limited to Report Q3, 2023 Results on Jan 30, 2023

Neurotech International Limited Announces Grant of FDA Pre-IND Meeting for NTI164 in ASD

Neurotech International Limited Announces Passing of Professor Allan Cripps AO, Non-Executive Director

Neurotech International Limited Announces Commencement of Patient Randomisation and First Patient Successfully Treats Under New Phase II/III NTIASD2 Clinical Trial for Children with Autism Spectrum Disorder

Less than half of directors are independent

Neurotech International Limited, Annual General Meeting, Nov 30, 2022

Neurotech International Limited, Annual General Meeting, Nov 23, 2022

Neurotech International Limited Reports Further Significant Clinical Improvement at 20 Weeks for Paediatric Autism Patients Treated with NTI164

Neurotech International Limited Announces New Phase I/II Clinical Trial in Children with PANDAS/PANS

Neurotech International Limited Provides Autism Spectrum Disorder Phase I/II Clinical Trial Update

Less than half of directors are independent

Neurotech International Limited Announces Transition of Alexandra Andrews from Chief Executive Officer to a New Position of Chief Operating Officer

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.015 loss in FY 2021)

Neurotech International Limited Announces Currently Finalising a Pivotal Phase II/III Clinical Trial Design to be Conducted in Australia

Neurotech International ORDINARY FULLY PAID to Be Deleted from OTC Equity

Neurotech International Limited Announces Executive Changes

Neurotech International Limited Announces Results with NTI164 in Paediatric ASD

High number of new directors

Neurotech International Limited Announces Important Developments Relating to the Study Protocol Assessing NTI164 in Children with Autism Spectrum Disorder

High number of new directors

Neurotech International Limited Announces Successful Developments Relating to Safety and Tolerability of NTI164 and Key Behavioural Parameters That Impact Autism Spectrum Disorder Patients

Neurotech International Limited Appoints Alexandra Andrews as Chief Executive Officer, Effective 8 March 2022

Neurotech International Limited Announces Nti164 Clinical Program Update

Full year 2021 earnings released: AU$0.015 loss per share (vs AU$0.011 loss in FY 2020)

Neurotech International Limited Announces the Continuation of Its Pre-Clinical Program in Neuro-Inflammatory Disease Models In-Line with Research and Development Pathway

Neurotech International Limited Initiates Phase I/II Open Label Study into Autism

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 2 million.

Neurotech International Limited Announces Strategic Cultivation Partnership with CannaPacific Limited

Neurotech International Limited Announces the Expansion of Its Exclusive License with Dolce Cann Global Pty Ltd

Neurotech International Limited Provides an Update on Clinical Study Program

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Neurotech International Limited Announces Initiation of Clinical Product Formulation Studies

Neurotech International Limited Announces Transition of Peter Griffiths as CEO

Neurotech International Limited Commences Landmark in Vitro Trials of Unique Cannabis Strains

Full year earnings released - AU$0.011 loss per share

Shareholder Returns

Price Volatility

About the Company

Neurotech International Limited Fundamentals Summary

19.9x

-12.4x

Earnings & Revenue